Long‑lasting stable disease with mTOR inhibitor treatment in a patient with a perivascular epithelioid cell tumor: A case report and literature review

Flechter,Ezequiel; Zohar,Yaniv; Guralnik,Ludmila; Passhak,Maria; Sela,Gil Bar

doi:10.3892/ol.2016.5231

Long‑lasting stable disease with mTOR inhibitor treatment in a patient with a perivascular epithelioid cell tumor: A case report and literature review

Authors:
- Ezequiel Flechter
- Yaniv Zohar
- Ludmila Guralnik
- Maria Passhak
- Gil Bar Sela
View Affiliations

Affiliations: Division of Oncology, Rambam Health Care Campus and Faculty of Medicine, Technion‑Israel Institute of Technology, Haifa 31096, Israel, Pathology Institute, Rambam Health Care Campus and Faculty of Medicine, Technion‑Israel Institute of Technology, Haifa 31096, Israel, Computed Tomography Unit, Radiology Department, Rambam Health Care Campus and Faculty of Medicine, Technion‑Israel Institute of Technology, Haifa 31096, Israel
Published online on: October 6, 2016 https://doi.org/10.3892/ol.2016.5231
Pages: 4739-4743

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Perivascular epithelioid cell tumor (PEComa) of the small intestine is extremely rare, and there is no established treatment at the present time. In 10% of patients with PEComas, genetic alterations of tuberous sclerosis complex have been reported. These genetic alterations activate mechanistic target of rapamycin (mTOR) in AMP‑activated protein kinase and Ras/mitogen‑activated protein kinase pathways, resulting in high mTOR activity. Since 2007, several cases of treatment with mTOR inhibitors in advanced PEComa have been reported. The current study presents the case of a patient with small bowel PEComa that metastasized to the brain and lungs. Following resection of the brain metastasis, the patient was treated with everolimus, a mTOR inhibitor, resulting in improvement if the patient's quality of life and a long period of stable disease. In conclusion, the use of mTOR inhibitors as a first‑line treatment option in advanced PEComa patients appears to be reasonable, according to the increasing evidence from data observed from reported cases with this rare malignancy.

View Figures

View References

1	Folpe AL: Neoplasms with perivascular epithelioid cell differentiation (PEComas)World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Soft Tissue and Bone. Fletcher CDM. Unni KK and Mertens F: IARC Press; Lyon: pp. 221–223. 2002
2	Martignoni G, Pea M, Reghellin D, Zamboni G and Bonetti F: PEComas: The past, the present and the future. Virchows Arch. 452:119–132. 2008. View Article : Google Scholar : PubMed/NCBI
3	Doyle LA, Hornick JL and Fletcher CD: PEComa of the gastrointestinal tract: Clinicopathologic study of 35 cases with evaluation of prognostic parameters. Am J Surg Path. 37:1769–1782. 2013. View Article : Google Scholar : PubMed/NCBI
4	Hornick JL and Fletcher CD: PEComa: What do we know so far? Histopathology. 48:75–82. 2006. View Article : Google Scholar : PubMed/NCBI
5	Napolioni V, Moavero R and Curatolo P: Recent advances in neurobiology of Tuberous Sclerosis Complex. Brain Dev. 31:104–113. 2009. View Article : Google Scholar : PubMed/NCBI
6	Kenerson H, Folpe AL, Takayama TK and Yeung RS: Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol. 38:1361–1371. 2007. View Article : Google Scholar : PubMed/NCBI
7	Dickson MA, Schwartz GK, Antonescu CR, Kwiatkowski DJ and Malinowska IA: Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: Clinical and molecular correlates. Int J Cancer. 132:1711–1717. 2013. View Article : Google Scholar : PubMed/NCBI
8	Italiano A, Delcambre C, Hostein I, Cazeau AL, Marty M, Avril A, Coindre JM and Bui B: Treatment with the mTOR inhibitor temserolimus in patients with malignant PEComa. Ann Oncol. 21:1135–1137. 2010. View Article : Google Scholar : PubMed/NCBI
9	Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, Vena N, Ligon AH, Antonescu CR, Ramaiya NH, Demetri GD, et al: Clinical activity of mTOR inhibitor with sirolimus in malignant perivascular epithelioid cell tumors: Targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 28:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
10	Bunch K and Sunde J: Fertility sparing treatment of a malignant uterine perivascular epithelioid cell tumor: A case report. Gynecol Oncol Case Rep. 8:14–16. 2014. View Article : Google Scholar : PubMed/NCBI
11	Benson C, Vitfell-Rasmussen J, Maruzzo M, Fisher C, Tunariu N, Mitchell S, Al-Muderis O, Thway K, Larkin J and Judson I: A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: The royal marsden hospital experience. Anticancer Res. 34:3663–3668. 2014.PubMed/NCBI
12	Gennatas C, Michalaki V, Kairi PV, Kondi-Paphiti A and Voros D: Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor. World J Surg Oncol. 10:1812012. View Article : Google Scholar : PubMed/NCBI
13	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
14	Agaimy A and Wünsch PH: Perivascular epithelioid cell sarcoma (malignant PEComa) of the ileum. Pathol Res Pract. 202:37–41. 2006. View Article : Google Scholar : PubMed/NCBI
15	Yanai H, Matsuura H, Sonobe H, Shiozaki S and Kawabata K: Perivascular epithelioid cell tumor of the jejunum. Pathol Res Pract. 199:47–50. 2003. View Article : Google Scholar : PubMed/NCBI
16	Parfitt JR, Keith JL, Megyesi JF and Ang LC: Metastatic PEComa to the brain. Acta Neuropathol. 112:349–351. 2006. View Article : Google Scholar : PubMed/NCBI
17	Bergamo F, Maruzzo M, Basso U, Montesco MC, Zagonel V, Gringeri E and Cillo U: Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa). World J Surg Oncol. 12:462014. View Article : Google Scholar : PubMed/NCBI